EyePoint, Inc.
No SEC Form 4 filings for $EYPT in the last 30 days.
Guggenheim named Eyepoint Pharmaceuticals (EYPT) its top biotech pick, setting a $68 price target based on a sum-of-the-parts NPV for Duravyu in retinal disorders and the company’s expected year-end 2025 cash. Guggenheim cited Phase 3 LUGANO topline data on track for Aug 2026 and LUCIA guidance to Q4 2026, with an NDA filing after LUCIA.
EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments – Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivota
Mizuho analyst Graig Suvannavejh named EyePoint, Inc. (EYPT) its top biotech small/mid-cap pick, raising its price target to $39 from $36 and keeping an Outperform rating. The catalyst is next month’s Phase 3 LUGANO top-line data for Duravyu in wet AMD. Mizuho models 75% probability of success and peak 2040 risk-adjusted revenue of $1.4B.
Over the past 7 days, alphai's AI scored 2 news stories mentioning EYPT (EyePoint, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent EYPT coverage spans financial news, corporate actions and sector analysis.
The article is primarily an analyst thesis and valuation update tied to upcoming retinal-disorder trial readouts.
Near-term catalyst is the LUGANO wet AMD topline readout in August 2026, supported by continued DSMC approval and cash runway into Q4 2027.
The article is a bullish catalyst framing around upcoming Phase 3 readout plus a higher modeled probability of success.
Analyst PT increase and higher modeled Phase 3 success probability can support near-term sentiment into upcoming pivotal trial readouts.
The filing signals ongoing federal compliance oversight, which can increase operating costs and constrain promotional/clinical activities.
alphai scores every news story that mentions EYPT with an AI model for sentiment and relevance, and aggregates insider trades from EyePoint, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim named Eyepoint Pharmaceuticals (EYPT) its top biotech pick, setting a $68 price target based on a sum-of-the-parts NPV for Duravyu in retinal disorders and the company’s expected year-end 2025 cash. Guggenheim cited Phase 3 LUGANO topline data on track for Aug 2026 and LUCIA guidance to Q4 2026, with an NDA filing after LUCIA.
3 min readEyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments – Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivota
6 min readMizuho analyst Graig Suvannavejh named EyePoint, Inc. (EYPT) its top biotech small/mid-cap pick, raising its price target to $39 from $36 and keeping an Outperform rating. The catalyst is next month’s Phase 3 LUGANO top-line data for Duravyu in wet AMD. Mizuho models 75% probability of success and peak 2040 risk-adjusted revenue of $1.4B.
4 min readMizuho raised its EyePoint Inc. (NASDAQ:EYPT) price target to $39 from $36 and kept an Outperform rating. It increased its Phase 3 success probability to 75% from 70% after channel checks, ahead of expected Phase 3 LUGANO top-line data next month for Duravyu in wet age-related macular degeneration. EyePoint is also expected to report LUCIA data afterward.
3 min readEyePoint, Inc. (EYPT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 eypt-ex10_2.htm EX-10.2 EX-10.2 Exhibit 10.2 CORPORATE INTEGRITY AGREEMENT BETWEEN THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND EYEPOINT INC. I. PREAMBLE EyePoint Inc. and all subsidiaries and any additional affiliated entities owne
3 min readWall Street analyst actions on Thursday included JPMorgan upgrading BlackRock to overweight, raising its Dec-2026 price target to $1,364, and increasing 2026-2027 estimates. JPMorgan reiterated JPMorgan as buy with a $420 target. Other calls covered Amazon (overweight, $335 target), Nvidia (Seaport sell), Apple (outperform), and multiple initiations or rating changes across semis, telecom, and retail.
3 min readEyePoint, Inc. (Nasdaq: EYPT) appointed Tarek S. Hassan, M.D. as Senior Vice President and Chief Strategic Science Officer. The company said he will guide clinical development, commercialization, and pipeline strategy, including DURAVYU (vorolanib intravitreal insert). EyePoint expects Phase 3 wet AMD topline data in mid-2026. Stock options for 100,000 shares were granted as an inducement award.
3 min readMizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.
4 min readEyePoint, Inc. (EYPT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001314102 0001314102 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18,
3 min readEyePoint, Inc. announced the granting of non-statutory stock options to fourteen new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover 362,500 shares of EyePoint common stock, with an exercise price of $14.63 per share, vesting over four years. The company is focused on developing and commercializing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase 3 trials.
2 min read
